Loading cancer entity…
Loading cancer entity…
Clinical trials
4,037 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (703)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04327037 | Safety of Expanded Haploidentical Natural Killer Cells for Leukemia | completed | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03922477 | A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 13 | Hoffmann-La RocheINDUSTRY | 1 | Feb 21, 2022 |
| clinicaltrials |
| NCT03647800 | Study of APVO436 in Patients With AML or MDS | unknown | Phase 1 | 136 | Aptevo Research and Development LLCINDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT03761069 | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias | terminated | Phase 1 | 33 | PTC TherapeuticsINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03441555 | A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 36 | AbbVieINDUSTRY | 3 | Feb 1, 2022 | clinicaltrials |
| NCT01578954 | Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction | completed | Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT03072043 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | completed | Phase 1 / Phase 2 | 55 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT03412292 | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT04187495 | Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | unknown | Phase 1 | 30 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT02914977 | Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia | completed | Phase 1 | 18 | Tara LinOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT02083250 | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT05023707 | Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT03459859 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | completed | Phase 1 | 12 | Justin Watts, MDOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05149339 | Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia | completed | Phase 1 / Phase 2 | 38 | Zagazig UniversityOTHER_GOV | 1 | Dec 8, 2021 | clinicaltrials |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | terminated | Phase 1 | 9 | AbbVieINDUSTRY | 3 | Dec 7, 2021 | clinicaltrials |
| NCT04973618 | Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML | withdrawn | Phase 1 | 0 | Aptevo TherapeuticsINDUSTRY | 0 | Dec 1, 2021 | clinicaltrials |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | terminated | Phase 1 | 3 | University of Southern CaliforniaOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 32 | OncoTherapy Science, Inc.INDUSTRY | 1 | Nov 24, 2021 | clinicaltrials |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) | terminated | Phase 1 / Phase 2 | 10 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT02660281 | URMC Related Haplo-identical Donor BMT(HaploOnly) | completed | Phase 1 | 74 | University of RochesterOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT02770820 | Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 9 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05100303 | A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT03263637 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT03144245 | Study of AMV564 in Patients With AML | completed | Phase 1 | 53 | Amphivena Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 74 | Daiichi SankyoINDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | withdrawn | Phase 1 | 0 | Medigene AGINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02464657 | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT02328755 | Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 37 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT03018223 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03625505 | A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 61 | AbbVieINDUSTRY | 1 | Sep 14, 2021 | clinicaltrials |
| NCT04126707 | The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans | completed | Phase 1 | 6 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Sep 8, 2021 | clinicaltrials |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | terminated | Phase 1 | 12 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01020539 | Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia(AML/MDS/JMML) | completed | Phase 1 | 18 | Columbia UniversityOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01221857 | Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 12 | Gamida Cell ltdINDUSTRY | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT03555955 | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | completed | Phase 1 | 21 | Jazz PharmaceuticalsINDUSTRY | 2 | Jul 22, 2021 | clinicaltrials |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | terminated | Phase 1 / Phase 2 | 22 | University of Illinois at ChicagoOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT04082286 | Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia | completed | Phase 1 | 9 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Jun 25, 2021 | clinicaltrials |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | completed | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2021 | clinicaltrials |
| NCT01787474 | Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01926587 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | completed | Phase 1 / Phase 2 | 45 | Traws Pharma, Inc.INDUSTRY | 2 | Jun 16, 2021 | clinicaltrials |
| NCT01861002 | A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | completed | Phase 1 | 15 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Jun 9, 2021 | clinicaltrials |
| NCT04762485 | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Mar 2, 2022source: clinicaltrials